NCT01055795 - Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

May 31, 2012

Conditions

Advanced Solid Tumors

Interventions

DRUG

Bevacizumab, Everolimus and LBH589

"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds"

Trial Locations (1)

27710

Duke University Medical Center, Durham